NASDAQ · Biotechnology

Arcellx, Inc. (ACLX) Stock

$115.07 +0.02% NASDAQ: ACLX Healthcare

Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases.

Valuation

MetricValue
Price$115.07
Market Cap$6.73B
P/E Ratio-28.27
P/B Ratio16.10
P/S Ratio302.09
EPS (TTM)$-4.07
52-Week High$115.13
52-Week Low$50.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-55.42%
ROA-37.90%
ROCE-50.64%
Gross Margin-64.81%
Operating Margin-1150.00%
Net Margin-1040.91%
Debt/Equity0.24
Current Ratio4.44

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$110.0M$108.0M$22.0M
Operating Profit$-65.0M$-191.0M$-90.0M$-138.0M$-253.0M
Net Profit$-65.0M$-189.0M$-71.0M$-107.0M$-229.0M
EPS$-1.94$-4.28$-1.47$-2.00$-4.07
Op Margin——-81.5%-127.5%-1135.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$129.0M$314.0M$825.0M$711.0M$604.0M
Total Liabilities$250.0M$109.0M$340.0M$257.0M$202.0M
Cash$31.0M$64.0M$395.0M$106.0M$80.0M
Borrowings$0$88.0M$98.0M$54.0M$96.0M

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-54.0M$-99.0M$208.0M$-83.0M$-210.0M
Investing Cash Flow$-86.0M$-120.0M$-176.0M$-196.0M$84.0M
Financing Cash Flow$-1.0M$2.0M$9.0M$0$-38.0M
Net Cash Flow$-16.0M$36.0M$332.0M$-291.0M$-25.0M
Free Cash Flow$-60.0M$-102.0M$186.0M$-97.0M$-213.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.44
EV / EBITDA-34.09
FCF Yield-3.16%
Quick Ratio4.44
Interest Coverage-10.45
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held11.67%
Institutions Held90.33%
Institutions Float Held102.27%
Institutional HolderSharesReport Date
T. Rowe Price Investment Management, Inc.10,560,4252025-12-31
Gilead Sciences Inc6,720,8032025-12-31
Paradigm Biocapital Advisors LP5,724,0162025-12-31
Vanguard Group Inc4,081,5192025-12-31
FMR, LLC3,563,7282025-12-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AKROAkero Therapeutics, Inc. $54.65 +0.00% -19.87 $4.50B 0.00%
ALKS $50.71 -3.84% 25.87 $8.45B 0.00%
ARWR $86.01 +1.61% -7397.00 $12.12B 0.00%
CRSP $46.73 +0.41% -12.98 $4.51B 0.00%
IMVT $39.24 +1.91% -11.09 $8.06B 0.00%

About Arcellx, Inc.

Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.

Arcellx, Inc. is headquartered in US.

Arcellx, Inc. (ACLX) stock trades at $115.07 with a market capitalization of $6.73B. The stock is valued at a price-to-earnings (P/E) ratio of -28.27, price-to-book of 16.10, price-to-sales of 302.09. Over the past 52 weeks the stock has ranged between $50.85 and $115.13, and currently trades at its 52-week high.

On profitability, Arcellx, Inc. generates a return on equity (ROE) of -55.42%, return on capital employed of -50.64%, an operating margin of -1150.00%, a net profit margin of -1040.91%.

Official website: arcellx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides